Pfizer (NYSE:PFE) has agreed to pay $55 million plus interest to settle allegations of misbranding by a subsidiary, according to a statement from the Department of Justice. The company's Wyeth unit is accused of promoting a drug for purposes other than those approved by the Food and Drug Administration.
Wyeth only had FDA approval to promote the drug, Protonix, for short-term treatment of one form of gastro-esophageal reflux disease. The government accused the company of promoting it as a treatment for all forms of the affliction, as well as for nighttime heartburn.
Wyeth allegedly conducted this promotion for nearly one and a half years, starting in early 2000.
Pfizer acquired Wyeth in 2009. In a statement quoted by the Associated Press, Pfizer said it is not a target or subject of the DoJ's case.
Eric Volkman and The Motley Fool have no positions in Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.